# Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

> **NCT00038831** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 47 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Mylotarg
- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Anti-thymocyte globulin
- **PROCEDURE:** Stem cell transplant

## Key facts

- **NCT ID:** NCT00038831
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2005-03
- **Final completion:** 2006-10
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2012-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038831, "Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00038831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*